Treatment of lupus nephritis with abatacept: The abatacept and cyclophosphamide combination efficacy and safety study

Arthritis and Rheumatology

Volumn 66, Issue 11, 2014, Pages 3096-3104

  Wofsy, David ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; AZATHIOPRINE; CREATININE; CYCLOPHOSPHAMIDE; PREDNISONE; ANTIBODY CONJUGATE; ANTIRHEUMATIC AGENT;

ADD ON THERAPY; ADULT; ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY FUNCTION; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL; DOSE RESPONSE; DRUG COMBINATION; LUPUS NEPHRITIS; TIME; TREATMENT OUTCOME;

ADULT; ANTIRHEUMATIC AGENTS; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOCONJUGATES; LUPUS NEPHRITIS; MALE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84924812141     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38790     Document Type: Article

References (34)

1. Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, FitzGerald JD, et al., American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 2012; 64: 797-808.
2. Austin HA III, Klippel JH, Balow JE, Le Riche NG, Steinberg AD, Plotz PH, et al., Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 614-9.
3. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, et al., Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46: 2121-31.
4. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, et al., The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 2010; 69: 61-4.
5. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, et al., Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219-28.
6. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al, and the Aspreva Lupus Management Study Group. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009; 20: 1103-12.
7. Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, et al, for the ALMS Group. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011; 365: 1886-95.
8. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, et al, for the Hong Kong-Guangzhou Nephrology Study Group. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000; 343: 1156-62.
9. Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al, for the LUNAR Investigator Group. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012; 64: 1215-26.
10. Lenschow DJ, Walunas TL, Bluestone JA,. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996; 14: 233-58.
11. Bahlis NJ, King AM, Kolonias D, Carlson LM, Liu HY, Hussein MA, et al., CD28-mediated regulation of multiple myeloma cell proliferation and survival. Blood 2007; 109: 5002-10.
12. Nair JR, Carlson LM, Koorella C, Rozanski CH, Byrne GE, Bergsagel PL, et al., CD28 expressed on malignant plasma cells induces a prosurvival and immunosuppressive microenvironment. J Immunol 2011; 187: 1243-53.
13. Njau MN, Kim JH, Chappell CP, Ravindran R, Thomas L, Pulendran B, et al., CD28-B7 interaction modulates short- and long-lived plasma cell function. J Immunol 2012; 189: 2758-67.
14. Daikh DI, Wofsy D,. Reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol 2001; 166: 2913-6.
15. 1 mice by a mechanism downstream of renal immune complex deposition. J Immunol 2003; 171: 489-97.
16. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al., Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition [published erratum appears in N Engl J Med 2005;353:2311]. N Engl J Med 2005; 353: 1114-23.
17. Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al., Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006; 144: 865-76.
18. Wofsy D, Hillson JL, Diamond B,. Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. Arthritis Rheum 2012; 64: 3660-5.
19. Yu CC, Fornoni A, Weins A, Hakroush S, Maiguel D, Sageshima J, et al., Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med 2013; 369: 2416-23.
20. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al., The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
21. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al, on behalf of the International Society of Nephrology and Renal Pathology Society Working Group on the Classification of Lupus Nephritis. The classification of glomerulonephritis in systemic lupus erythematosus revisited [published erratum appears in J Am Soc Nephrol 2004;15:835-6]. J Am Soc Nephrol 2004; 15: 241-50.
22. McHorney CA, Ware JE Jr, Lu JF, Sherbourne CD,. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994; 32: 40-66.
23. Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, et al., The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993; 86: 447-58.
24. Dai Z, Lakkis FG,. The role of cytokines, CTLA-4 and costimulation in transplant tolerance and rejection. Curr Opin Immunol 1999; 11: 504-8.
25. Finck BK, Linsley PS, Wofsy D,. Treatment of murine lupus with CTLA4Ig. Science 1994; 265: 1225-7.
26. Illei GG, Austin HA, Crane M, Collins L, Gourley MF, Yarboro CH, et al., Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001; 135: 248-57.
27. Mok CC, Ying KY, Tang S, Leung CY, Lee KW, Ng WL, et al., Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum 2004; 50: 2559-68.
28. Moroni G, Longhi S, Giglio E, Messa P, Ponticelli C,. What happens after complete withdrawal of therapy in patients with lupus nephritis. Clin Exp Rheumatol 2013; 31: S75-81.
29. McCarty DJ, Manzi S, Medsger TA Jr, Ramsey-Goldman R, LaPorte RE, Kwoh CK,. Incidence of systemic lupus erythematosus: race and gender differences. Arthritis Rheum 1995; 38: 1260-70.
30. Fernandez M, Alarcon GS, Calvo-Alen J, Andrade R, McGwin G Jr, Vila LM, et al, for the LUMINA Study Group. A multiethnic, multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE. Arthritis Rheum 2007; 57: 576-84.
31. Pons-Estel GJ, Alarcon GS,. Lupus in Hispanics: a matter of serious concern. Cleve Clin J Med 2012; 79: 824-34.
32. Richman IB, Taylor KE, Chung SA, Trupin L, Petri M, Yelin E, et al., European genetic ancestry is associated with a decreased risk of lupus nephritis. Arthritis Rheum 2012; 64: 3374-82.
33. Gonzalez LA, Toloza SM, McGwin G Jr, Alarcon GS,. Ethnicity in systemic lupus erythematosus (SLE): its influence on susceptibility and outcomes. Lupus 2013; 22: 1214-24.
34. Feldman CH, Hiraki LT, Liu J, Fischer MA, Solomon DH, Alarcon GS, et al., Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004. Arthritis Rheum 2013; 65: 753-63.